A Real-World Evaluation of Clinical Outcomes of Biologicals and Bronchial Thermoplasty for Severe Refractory Asthma (BIOTERM).

BACKGROUND: The important progress made on asthma phenotyping encouraged the development of new therapeutic strategies, such as monoclonal antibodies (mAbs) and bronchial thermoplasty (BT). The aim of this study is to compare patients diagnosed with severe refractory asthma (SRA) who are currently being treated with omalizumab, mepolizumab, benralizumab or BT and to evaluate the efficacy of these treatments over a 12-month observation period.
METHODS: Overall, 199 consecutive patients with SRA were included. The cohort was selected referring to the eligibility criteria for all available biologics and BT.
RESULTS: Among 32 patients treated with benralizumab, we found a 16.7% reduction in hospitalizations, a 66.6% reduction in exacerbations (p = 0.0001) and the greater improvement in FEV1 (+ 37.4%, p < 0.0001). Among omalizumab group (54 patients), there was a 85.7% (p = 0.012) reduction in hospitalizations and a 88.8% (p < 0.0001) reduction in exacerbations. In the mepolizumab group (83 patients), we found a 89.5% (p = 0.02) reduction in hospitalizations and a 92.1% (p < 0.0001) reduction in exacerbations. BT subgroup (30 patients) showed a 93.7% (p = 0.001) reduction in hospitalizations and a 73.5% (p < 0.0001) reduction in exacerbations. The best results in terms of OCS sparing effect were obtained by BT (- 76%, p < 0.0001) and mepolizumab (- 90.2%, p = 0.002). Omalizumab showed the highest percentage of super responder patients.
CONCLUSION: To our knowledge, this is the first study to compare all marketed mAbs with BT, ending in more comprehensive and applicable results to clinical practice. All biologics, to varying degrees, reduced hospitalizations, exacerbations, and OCS use. The starting point for patients in the BT group was worse regarding hospitalizations, exacerbations and OCS, but despite this, even this non-pharmacological option obtained positive results, comparable to biologics.

Introduction

Asthma is a very heterogeneous disease, varying from forms with mild bronchial obstruction to other serious ones, up to severe refractory asthma (SRA). Dividing the heterogeneity of asthma into phenotypes is complex due to the scarcity of specific and validated biomarkers. Most of the phenotyping process is mainly based on cross-sectional, retrospective, epidemiological data, symptom pattern, atopic state, bronchial obstruction pattern and others.1 These clinical phenotypes often overlap and can sometimes change over time.

Recent clinical and immunological phenotypic classifications of asthma encouraged the development of new therapeutic strategies, such as the discovery of monoclonal antibodies (mAbs) targeted to IgE (anti-IgE/omalizumab), or anti interleukin-5 (IL-5), specific for the Type 2 (T2)-high eosinophilic phenotype.2 Anti-IgE therapy with omalizumab was the first therapeutic option for the treatment of severe allergic asthma.

AntiIL-5 biologics such as mepolizumab and reslizumab and anti IL-5 receptor alpha subunit such as benralizumab have recently been approved as add-on treatments in patients with severe eosinophilic refractory asthma. To date, other drugs are being developed aimed at treating the T2-high phenotype. Despite these great advances, knowledge is still limited regarding other potential phenotypes and endotypes of severe asthma, such as non-eosinophilic asthma and the T2-low phenotype (neutrophilic and paucigranulocytic).3

To date, bronchial thermoplasty (BT) is mainly addressed as a therapy for the T2-low asthma endotype. It is an endoscopic procedure approved by the US Food and Drug Administration (FDA) in 2010 for the treatment of severe asthma.4 BT is a non-drug option for the treatment of moderate-to-severe refractory asthma based on the release of controlled heat at 65°C aimed at modifying the structure of the bronchial wall by reducing the amount of smooth muscle. The device used for BT is a catheter called Alair System (Boston Scientific, Natick, MA, USA).5

There are currently no comparative studies between the different biologics and BT in a real-world context. Furthermore, BT is still considered a procedure to be reserved almost exclusively for patients not eligible for biologics and probably less effective than mAbs. For these reasons, it is important to obtain data that allow comparison of pharmacological and non-pharmacological options in the different phenotypes of patients with severe asthma.

In light of the different therapeutic options available for the treatment of SRA, the rationale of the present study is to compare patients diagnosed with severe asthma who are currently being treated with omalizumab, mepolizumab, benralizumab and BT and to evaluate the efficacy of these treatments over a 12-month observation period.

Methods

Ethical Approval

This study was approved by the local ethics committee (Ethics Committee of the Vast Emilia North Area - Azienda USL di Reggio Emilia- IRCCS, Reggio Emilia 15/11/2017), protocol number 2020/0013491 and Ethics Committee of University “Luigi Vanvitelli” – AORN “Ospedali dei Colli” protocol number 11652/2020. This protocol was performed according to the Good Clinical Practice (ICH Harmonized Tripartite Guidelines for Good Clinical Practice 1996; Directive 91/507. EEC, The Rules Governing Medical Produced in the European Community) and in compliance with Italian laws (D.L.vo n.211 of 24 June 2003; D.L. n.200 of 6 November 2007; MD of 21 December 2007).

Study Population

In this retrospective real-life study, patients enrolled were aged >12 years and suffered from SRA according to ERS/ATS severe asthma guidelines 2019 and GINA 2020;6,7 they were referred to the Pulmonology Unit of AUSL of Reggio Emilia/IRCCS in Reggio Emilia, Italy and in Department of Pulmonology, Monaldi Hospital, Naples, Italy, since January 2019 to January 2020.

For each patient, we collected the following data: demographic data (age, sex, age of onset of asthma, history of smoking, presence of allergies, comorbidities); clinical data (lung function, exacerbations, emergency department (ED) visits and hospitalizations); patient-reported outcomes (asthma quality of life questionnaire - AQLQ, asthma control questionnaire - ACQ); serum biomarkers (blood eosinophil count and total serum IgE); drug therapies for asthma (inhaled corticosteroids/long-acting β-adrenoceptor agonists (ICS/LABA), long-acting muscarinic antagonists (LAMA), leukotriene receptor antagonists (LTRA), theophylline, oral corticosteroids (OCS), biologics (omalizumab, mepolizumab and benralizumab) and BT.

The cohort was selected referring to the eligibility criteria for every biologic. Specifically, omalizumab criteria: age ≥6 and ≤75 years; total serum levels of IgE 76 ≤ IgE ≤ 1500 IU/L; ≥1 exacerbations of asthma that required OCS, ED visits or hospitalizations in the previous 12 months; positive result on skin prick test or specific serum IgE for a perennial allergen; forced expiratory volume (FEV1) <80% pre-bronchodilator (pre-BD). Mepolizumab criteria: age ≥18 years; elevated peripheral blood eosinophil count (≥150 cells/μL a screening or ≥300 cells/μL within 12 months prior to enrollment); ≥2 exacerbations of asthma requiring OCS, ED visits or hospitalizations in the previous 12 months. Benralizumab criteria: age ≥18 ≤ 75 years; high peripheral blood eosinophil count (≥300 cells/μL in the previous 12 months before enrollment); ≥2 exacerbations of asthma requiring OCS, ED visits or hospitalizations within the previous 12 months. BT criteria: age ≥18 years; ≥2 exacerbations of asthma requiring OCS, ED visits or hospitalizations during the 12 months prior to study initiation; FEV1 > 60% pre-BD.

In detail, omalizumab was considered the biological treatment of choice for patients with severe non-eosinophilic allergic asthma, high blood IgE levels and at least one sensitization to a perennial allergen. Conversely, an anti-IL-5 biological agent was selected for patients with severe eosinophilic non-allergic asthma. Due to the lack of head-to-head comparative studies, currently there are no specific recommendations in order to choose among all available biologics targeting the IL-5 pathway. Regarding this, a matching-adjusted indirect comparison indicated that benralizumab and mepolizumab have similar efficacy profiles.8 Other indirect comparison studies between these two biologics showed conflicting data. For these reasons, there are no clear indications in choosing one of these two options at the moment.9,10

Patients undergoing BT were the ones who were ineligible for biologics, patients who had not responded to a biologic, or those who were unwilling to undergo biological therapy for life.

Regarding therapeutic switches, the most frequent reasons that led to the interruption of a biological therapy in order to start another one were the lack of symptom control or the patient’s request. No switches were caused by adverse events. We performed a direct switch between two treatments without a wash-out period.

Reslizumab and dupilumab were not considered because they were not available on market in Italy at the time of the study enrollment.

The exclusion criteria were:

Absence of signed informed consent;

Absence of a consent on privacy, data collection and analysis in aggregate form;

Absence of a diagnosis of severe asthma, made according to the definition of the document ERS/ATS 2014;

There were no other exclusion criteria, in order to allow a real-life view of the characteristics of these patients with severe asthma. All patients undergoing treatment for 1 year were included in the study, regardless of response to therapy.

Outcomes

Primary Endpoint

Measurement of the frequency of moderate-to-severe exacerbations in the 12 ± 2 months from the start of treatment. Moderate exacerbations were defined as deterioration of the patient’s symptoms or lung function beyond normal daily changes requiring drug modification. Severe exacerbations are defined on the basis of the need for urgent interventions, such as prescribing systemic steroids (oral or injected) or increasing the dose of maintenance steroids for at least 3 days, emergency room visits or hospitalization due to worsening of symptoms.

Secondary Endpoints

Proportion of super-responders (complete cessation of exacerbations, complete OCS withdrawal and little or no symptoms (ACT > 20 and ACQ < 1.5).

Dosage of standard care drugs (ICS/LABA/LAMA/LTRA).

Daily dosage of OCS.

Improvement of the quality of life (QoL) in terms of scores in AQLQ, ACT, ACQ questionnaires.

Statistical Analysis

Statistical analysis was performed with Prism 8.0 statistical software package (GraphPad Software, Inc., La Jolla, CA, USA). Demographic and clinical characteristics were analyzed and compared between groups at baseline and after the follow up, measuring also the variations of clinical features and outcomes within each group.

The paired t test and Wilcoxon test were used to compare two groups of continuous variables, while Kruskal–Wallis test, Brown-Forsythe test, and Welch ANOVA test were used to compare 4 groups of continuous variables. Chi-square test and Fisher's exact test were used for the comparison between categorical variables. A p value of less than 0.05 was considered statistically significant.

Results

Overall, 199 consecutive patients with SRA were included. Among these, 60% were female and the mean age was 56.5 ± 12.9 years, range 18–81 (Table 1). Of 199 patients, 65 (33%) were ex-smokers and pre-BD FEV1 was 68±18 of predicted. Regarding asthma concomitant medications, daily mean dose of ICS was 1045.2 ± 455.6 mcg, 140 (50%) patients took LAMA, 94 (34%) patients took LTRA and 97 (49%) of our study population received maintenance OCS at the time of enrollment. Fifty-four out of 199 patients (27%) took omalizumab, 83 (42%) took mepolizumab, 32 (16%) took benralizumab and 30 (15%) underwent BT.

Table 1

Demographics and Clinical Characteristics

	Overall Population	Benralizumab	Mepolizumab	Omalizumab	Bronchial Thermoplasty	p value
No. of subject (%)	199	32 (16)	83 (42)	54 (27)	30 (15)	NA
Age at enrollement, mean ± SD	56.5 ± 12.9	57.1 ± 12.5	57.2 ± 12.1	54.4 ± 15.6	57.6 ± 10.6	0.58
Female, n (%)	120 (60)	16 (50)	52 (63)	33 (61)	19 (63)	0.63
Age of onset, mean ± SD	33.8 ± 14.9	36.8 ± 14.9	34.6 ± 13.9	29.4 ± 16.9	36 ± 12.3	0.09
Former smokers, n (%)	65 (33)	8 (25)	34 (41)	17 (31)	6 (20)	0.12
Atopics, n (%)	130 (65)	15 (47)	50 (60)	54 (100)	11 (37)	<0.0001
Patients multi-sensitive, n (%)	75 (38)	10 (31)	27 (33)	31 (57)	7 (23)	0.0045
Chronic rhinosinusitis with Nasal Polyposis (CRSwNP), n (%)	66 (33)	14 (44)	20 (24)	20 (37)	12 (40)	0.13
Bronchiectasis, n (%)	50 (25)	11 (34)	19 (23)	7 (13)	0 (0)	0.0026
Gastroesophageal reflux disease (GERD), n (%)	78 (39)	14 (44)	32 (39)	16 (30)	16 (53)	0.18
Eosinophilic granulomatosis with polyangiitis (EGPA), n (%)	5 (2.5)	2 (6)	3 (4)	0 (0)	0 (0)	0.22
Osteoporosis, n (%)	34 (17)	7 (22)	12 (14)	4 (7)	11 (37)	0.006
ASA intolerance, n (%)	11 (5.5)	2 (6)	7 (8)	2 (4)	0 (0)	0.32
Obstructive Sleep Apnoea Syndrome (OSAS), n (%)	12 (6)	2 (6)	3 (4)	4 (7)	3 (10)	0.59
Allergic bronchopulmonary aspergillosis (ABPA), n (%)	11 (5.5)	2 (6)	3 (4)	6 (11)	0 (0)	0.13
Switch to other therapies, n (%)
Omalizumab	0	0 (0)	0	NA	0 (0)	NA
Mepolizumab	10 (5)	0 (0)	NA	6 (11)	4 (13)	0.12
Benralizumab	8 (4)	NA	5 (6)	2 (4)	1 (3)	0.75
Bronchial thermoplasty	8 (4)	0 (0)	0 (0)	8 (15)	NA	0.0001
Blood eosinophils mean ± SD, cells/ µL	535.6 ± 616.4	787.3 ± 905.2	623.9 ± 591.7	351.4 ± 362.7	348.3 ± 537.5	<0.0001
≥150 cells/ µ, n (%)	172 (86)	32 (100)	81 (98)	41 (76)	18 (60)	<0.0001
≥ 300 cells/ µ, n (%)	130 (65)	29 (91)	70 (84)	22 (41)	9 (30)	<0.0001
≥ 400 cells/ µ, n (%)	100 (50)	25 (78)	56 (67)	12 (22)	7 (23)	<0.0001
Total IgE, KU/L, mean ± SD	371.5 ± 624.2	353.7 ± 504.7	317.9 ± 507.7	577.4 ± 886.1	165.9 ± 288.8	<0.0001
Oral Corticosteroids, mg, mean ± SD	5.7 ± 8.2	4.4 ± 7.6	5.1 ± 7.1	2.4 ± 4.6	14.6 ± 10.4	<0.0001
Inhaled corticosteroids, mcg, mean ± SD	1045.2 ± 455.6	1126.2 ± 463.9	1072.5 ± 432.1	712.8 ± 282.2	1304.7 ± 601.6	<0.0001

The mean age of SRA onset was 33.8 ± 14.9 years old, 65% of the study population was atopic, 38% was sensitive to more than one aero-allergen and 65% was eosinophilic (blood eosinophil count (BEC) >300 cells/mL). An overlap among atopic and eosinophilic endotypes was present in 56 (28%) of patients.

Among 32 patients (16%) treated with benralizumab (Table 2), BEC was 787.3 ± 905.2 cells/mL at baseline and 0.0 ± 0.0 post-treatment (p < 0.0001), total IgE mean value was 353.7 ± 504.7 kU/L at baseline and 271.8 ± 428.2 post-treatment, Asthma Control Test (ACT) score increased by 4.2 points at the end of the treatment (EOT) (p < 0.0001), mean hospitalizations number per year was 0.4 ± 1.2 at baseline and 0.3 ± 1.1 (- 16.7%) at EOT, mean exacerbations number per year was 2.5 ± 2.6 at baseline and 0.8 ± 2 (−66.6%) (p = 0.0001) at EOT, FEV1 (L) was 1.8 ± 0.8 before benralizumab and 2.4 ± 1 (+ 37.4%) at the EOT (p < 0.0001). Regarding OCS, mean prednisone dose at baseline was 4.4 ± 7.6 mg at baseline and 3.4 ± 7.5 mg (−23.6%) at the EOT (p = 0.06) (Table 2 and Figure 1).

Table 2

Outcomes Variations in Benralizumab Group

Benralizumab
	Pre	Post	p value
Eos (cell/mcl), mean ± SD	787.3 ± 905.2	0.0 ± 0.0	<0.0001
Eos (%), mean ± SD	9.2 ± 5.3	0.06 ± 0.04	<0.0001
Neutr (cell/mcl), mean ± SD	4153 ± 1171	4212 ± 1615	0.86
Neutr (%), mean ± SD	49.9 ± 8.2	52.2 ± 14.5	0.28
IgE tot (kU/L), mean ± SD	310 ± 490.3	271.8 ± 428.2	0.09
ACT, mean ± SD	15.3 ± 3.9	17.8 ± 4.6	0.0009
ACQ, mean ± SD	3.4 ± 0.7	1.1 ± 1.4	<0.0001
AQLQ, mean ± SD	3.9 ± 1.2	4.4 ± 1	0.008
Hospitalizations in the last year, mean ± SD	0.4 ± 1.2	0.3 ± 1.1	0.32
Exacerbations in the last year, mean ± SD	2.5 ± 2.6	0.8 ± 2	0.0001
FEV1 (L), mean ± SD	1.8 ± 0.8	2.4 ± 1	<0.0001
FEV1 (%), mean ± SD	60 ± 19.8	80.9 ± 23.5	<0.0001
FVC (L), mean ± SD	2.8 ± 0.9	3.4 ± 1.3	<0.0001
FVC (%), mean ± SD	78.2 ± 19.1	93 ± 21.7	0.0003
FEV1/FVC, mean ± SD	63.9 ± 10	69.6 ± 12.2	0.04
ICS (mcg/die), mean ± SD	1126 ± 464	1095 ± 488.4	0.5
OCS (mg/die), mean ± SD	4.4 ± 7.7	3.4 ± 7.5	0.06
LAMA, n (%)	26 (81)	23 (72)	0.56
LTRA, n (%)	16 (50)	14 (44)	0.8
Theophylline, n (%)	5 (16)	5 (16)	>0.99

Figure 1

Comparison of changes in primary outcomes. Note: The * indicates a statistically significant difference between the groups.

Among omalizumab group (54 out of 199 patients, 27%), BEC was 351.4 ± 362.7 cells/mL at baseline and 327.3 ± 292.4 post-treatment, total IgE mean value was 577.4 ± 886.1 kU/L at baseline and 578 ± 621 post-treatment, ACT score increased by 7.2 points at the end of the treatment (p < 0.0001), mean hospitalization number per year was 0.3 ± 0.6 at baseline and 0.04 ± 0.2 (- 85.7%) (p = 0.012) at EOT, mean exacerbation number per year was 4.1 ± 2.1 at baseline and 0.5 ± 0.6 (- 88.8%) (p < 0.0001), FEV1 (L) was 1.9 ± 0.8 before omalizumab and 2.4 ± 1 (+ 4.7%) at the end of treatment period (Table 2). Regarding OCS, mean prednisone dose at baseline was 2.4 ± 4.6 mg and 0.6 ± 1.7 mg (- 75.7%) at EOT (p = 0.01) (Table 3 and Figure 1).

Table 3

Outcomes Variations in Omalizumab Group

Omalizumab
	Pre	Post	p value
Eos (cell/mcl), mean ± SD	325.8 ± 331.2	331.8 ± 293.5	0.86
Eos (%), mean ± SD	4.2 ± 3.6	4.4 ± 3.5	0.94
Neutr (cell/mcl), mean ± SD	4760 ± 2189	4498 ± 1478	0.76
Neutr (%), mean ± SD	58.1 ± 12.6	56.6 ± 7.8	0.69
IgE tot (kU/L), mean ± SD	586.8 ± 910.3	578 ± 621	0.91
ACT, mean ± SD	14.7 ± 3.7	21.9 ± 2	<0.0001
ACQ, mean ± SD	3 ± 0.7	1.8 ± 0.7	<0.0001
AQLQ, mean ± SD	4.8 ± 0.9	5.5 ± 0.8	0.0003
Hospitalizations in the last year, mean ± SD	0.3 ± 0.6	0.04 ± 0.2	0.012
Exacerbations in the last year, mean ± SD	4.1 ± 2.1	0.5 ± 0.6	<0.0001
FEV1 (L), mean ± SD	1.9 ± 0.8	2.2 ± 1	0.0006
FEV1 (%), mean ± SD	65.3 ± 13.3	73.7 ± 16.5	<0.0001
FVC (L), mean ± SD	3 ± 1.1	3.2 ± 1.3	0.15
FVC (%), mean ± SD	82.8 ± 15.9	85.8 ± 17.3	0.09
FEV1/FVC, mean ± SD	69.1 ± 12.3	69.3 ± 10.6	0.35
ICS (mcg/die), mean ± SD	798.8 ± 237	873.7 ± 345.6	0.21
OCS (mg/die), mean ± SD	2.4 ± 4.7	0.6 ± 1.7	0.006
LAMA, n (%)	27 (50)	23 (42.6)	0.56
LTRA, n (%)	33 (61)	29 (53.7)	0.56
Theophylline, n (%)	5 (9.3)	0 (0)	0.056

In the evaluation of 83 patients treated with mepolizumab (42%), BEC was 623.9 ± 591.7 cells/mL at baseline and 139.2 ± 389.9 post-treatment (p < 0.0001), total IgE mean value was 317.9 ± 507.7 kU/L at baseline and 229.2 ± 504.8 post-treatment (p = 0.03), ACT score increased by 7.4 points at the end of the treatment (p < 0.0001), mean hospitalization number per year was 0.3 ± 0.9 at baseline and 0.04 ± 0.2 (- 89.5%) (p = 0.02) at EOT, mean exacerbation number per year was 5 ± 2.3 at baseline and 0.4 ± 0.9 (- 92.1%) (p < 0.0001) at EOT, FEV1 (L) was 1.96 ± 0.85 before mepolizumab and 2.21 ± 0.78 (+ 11.9%) at the EOT period (p = 0.01). Regarding OCS, mean prednisone dose at baseline was 11 ± 26.9 mg and 1.1 ± 4.6 mg (- 90.2%) at EOT (p = 0.002) (Table 4).

Table 4

Outcomes Variations in Mepolizumab Group

Mepolizumab
	Pre	Post	p value
Eos (cell/mcl), mean ± SD	511.7 ± 238.5	139.2 ± 389.9	<0.0001
Eos (%), mean ± SD	6.9 ± 3.3	1.5 ± 2.2	<0.0001
Neutr (cell/mcl), mean ± SD	4498 ± 1684	5381 ± 1323	0.0004
Neutr (%), mean ± SD	54.6 ± 11.3	59.7 ± 7.5	0.003
IgE tot (kU/L), mean ± SD	336.3 ± 529	229.2 ± 504.8	<0.0001
ACT, mean ± SD	15.3 ± 4.2	22.7 ± 2.5	<0.0001
ACQ, mean ± SD	3.6 ± 0.6	2.3 ± 0.9	<0.0001
AQLQ, mean ± SD	3.9 ± 1.1	5.1 ± 1	0.001
Hospitalizations in the last year, mean ± SD	0.3 ± 0.9	0.03 ± 0.2	0.02
Exacerbations in the last year, mean ± SD	5 ± 2.3	0.4 ± 0.9	<0.0001
FEV1 (L), mean ± SD	1.9 ± 0.8	2.2 ± 0.8	<0.0001
FEV1 (%), mean ± SD	70.9 ± 19.7	82.3 ± 15.9	<0.0001
FVC (L), mean ± SD	2.7 ± 1	3 ± 1.1	<0.0001
FVC (%), mean ± SD	83.6 ± 16.2	93.2 ± 14.6	<0.0001
FEV1/FVC, mean ± SD	68.2 ± 11	72.4 ± 8.9	0.002
ICS (mcg/die), mean ± SD	1086 ± 413.4	1072 ± 425.6	0.79
OCS (mg/die), mean ± SD	11 ± 27.8	1.1 ± 4.6	0.002
LAMA, n (%)	70 (84.3)	55 (63.3)	0.01
LTRA, n (%)	34 (41)	22 (26.5)	0.07
Theophylline, n (%)	6 (7.2)	0 (0)	0.03

Within the subgroup of 30 patients who underwent BT (15%), BEC was 348.3 ± 537.5 cells/mL at baseline and 392 ± 284.3 post-treatment, total IgE mean value was 165.9 ± 288.8 kU/L at baseline and 166.5 ± 192.9 post-treatment (p = 0.03), ACT score increased by 5.9 points at EOT (p < 0.0001), mean hospitalization number per year was 1.1 ± 1.6 at baseline and 0.07 ± 0.2 (- 93.7%) (p = 0.001) at EOT, mean exacerbation number per year was 5.6 ± 3.4 at baseline and 1.5 ± 1 (- 73.5%) (p < 0.0001) at EOT, FEV1 (L) was 1.9 ± 0.8 before BT and 2.2 ± 1 (+ 5.7%) at EOT period (Figure 1). Regarding OCS, mean prednisone dose at baseline was 14.7 ± 10.2 mg and 3.5 ± 4.9 (−76%) after BT (p < 0.0001) (Table 5).

Table 5

Outcomes Variations in Bronchial Thermoplasty Group

	Bronchial Thermoplasty
	Pre	Post	p value
Eos (cell/mcl), mean ± SD	365 ± 552.8	392 ± 284.3	0.77
Eos (%), mean ± SD	3.8 ± 5.6	4.9 ± 3.4	0.28
Neutr (cell/mcl), mean ± SD	4557 ± 2058	4363 ± 1679	0.41
Neutr (%), mean ± SD	51.8 ± 14.5	50.1 ± 11.7	0.47
IgE tot (kU/L), mean ± SD	137.1 ± 152.3	166.5 ± 192.9	0.54
ACT, mean ± SD	13.9 ± 3.8	19.9 ± 4.4	<0.0001
ACQ, mean ± SD	3.2 ± 0.9	2.1 ± 0.9	<0.0001
AQLQ, mean ± SD	3.6 ± 1.1	4.8 ± 1.2	0.0004
Hospitalizations in the last year, mean ± SD	1.1 ± 1.6	0.07 ± 0.2	0.001
Exacerbations in the last year, mean ± SD	5.6 ± 3.4	1.5 ± 1	<0.0001
FEV1 (L), mean ± SD	2 ± 0.7	2.2 ± 0.8	0.29
FEV1 (%), mean ± SD	71.2 ± 19.6	70.6 ± 21.2	0.77
FVC (L), mean ± SD	3.3 ± 0.9	3.2 ± 1	0.18
FVC (%), mean ± SD	92.3 ± 17.3	84 ± 18.5	0.004
FEV1/FVC, mean ± SD	65.8 ± 15	69.2 ± 12.9	0.13
ICS (mcg/die), mean ± SD	1255 ± 592	1393 ± 595.7	0.26
OCS (mg/die), mean ± SD	14.7 ± 10.2	3.5 ± 4.9	<0.0001
LAMA, n (%)	17 (56.7)	23 (76.7)	0.17
LTRA, n (%)	11 (36.7)	5 (16.7)	0.14
Theophylline, n (%)	5 (16.7)	1 (3.3)	0.19

The proportion of super responders was 47% (15) in benralizumab group, 58% (48) in mepolizumab group, 61% (33) in omalizumab group and 10% (3) in BT group (p < 0.0001). In detail, the proportion of patients who weaned off from OCS was 72% (23) in benralizumab group, 69% (57) in mepolizumab group, 89% (48) in omalizumab group and 53% (16) in BT group (p=0.013). The proportion of patients who achieved good symptom control was 59% (19) in benralizumab group, 85% (71) in mepolizumab group, 85% (46) in omalizumab group and 33% (10) in BT group (p < 0.0001). Finally, the proportion of patients with partial response and who may require a treatment switch was 16% (5) in benralizumab group, 10% (8) in mepolizumab group, 5.5% (3) in omalizumab group and 10% (3) in BT group (p=0.32).

The improvement in ACQ score was statistically significant for all treatment options while AQLQ improved significantly for all treatments except benralizumab (Figure 2 and ). Altogether, few therapeutic switches occurred in the cohort of patients examined, with the highest number occurring among subjects treated with omalizumab and then undergoing BT (8 patients, 27%). Five patients (16%) treated with mepolizumab then received benralizumab. Therapeutic switches between the other groups were infrequent. Regarding OCS use in this subgroup, there are no differences between the means of patients who received omalizumab before BT versus those who did BT alone (at baseline, respectively, 18.33 mg/patient/day ± 10.80 and 13.75 ± 10.11 with p = 0.38 while after BT 5.83 ± 5.63 and 2.91 ± 4.59 with p = 0.28); as a difference, in both groups the variations are statistically significant, in patients who first received omalizumab the difference is −12.5 ± 10.25 with p = 0.03, while in patients who received BT alone it is −10.84 ± 9.25 with p < 0.0001.

Figure 2

Comparison of changes in ACT, ACQ and AQLQ scores. The * indicates a statistically significant difference between the groups. The range markers stand for the standard deviation.

As for standard care drugs, a significant reduction was found only for LAMA, LTRA and theophylline in the mepolizumab group ().

Safety Profile

No mild or severe side effects were observed throughout the treatment period.

Discussion

In literature there is only one real-world comparison study between BT and biologics, only including mepolizumab but not the other available agents. It was a single-center, observational cohort study on 91 patients, which showed that after 12 months there were no differences between treatment outcomes evaluating ACQ, reduction of exacerbation rate and OCS dose.11 Unlike this study, ours compare all marketed mAbs at the time of patient enrolment with BT, ending in more comprehensive and applicable results to clinical practice.

To our knowledge, this is the first study to compare not only different biologicals but also a non-drug treatment option such as BT in a real-life setting. This study presents comparative results from a large cohort of severe refractory severe asthma patients treated in two referral centers with all biologics available at the time of enrollment and with BT. There are currently no prospective head-to-head comparative studies from different biologics and BT, so these data could be extremely useful for clinical practice and for making the difficult choice between different therapeutic options, especially in the case of phenotypic overlap. The increasing availability of different therapeutic approaches implies a careful selection of severe asthma patients, based on clinical evaluation and identification of available biomarkers. The combination of these data allows to identify specific phenotypes and molecular targets that can guide the choice of the correct treatment option. As for biological drugs, the choice is supported by biomarkers. As for now, no real biomarker for BT is available, the choice of which usually takes place in case of patients who are not eligible for biologics or refractory to them. In our cohort, patients eligible to BT were selected based on lung function (FEV1 > 60%), also in light of the inclusion criteria of the AIR1 study.12 Recent studies applied other eligibility criteria, such as FEV1 < 50%,13 but these data refer to a small population. The difficult choice between different therapeutic options, the lack of head-to-head data and above all the absence of predictive biomarkers sometimes lead to the need of carrying out therapeutic switches as often reported in literature and as shown in a previous study we published.14 Although the number of patients treated with single biologics and with BT differs not only in terms of characteristics but also in terms of sample size, the data obtained are extremely interesting and surprising for various aspects. In general, the effectiveness of biologics and BT is confirmed, but some unexpected data emerge by analyzing in detail every parameter examined.

The largest patient subgroup was the one treated with mepolizumab (83), which had a higher mean OCS dose at baseline than other biologics (10.8 mg), likely indicative of greater asthma severity. At the end of the observation period, a high OCS sparing effect was confirmed with almost complete weaning from OCS (mean residual dose 1.1 mg). The improvement in FEV1, ACT, ACQ and AQLQ scores was significant, although the improvement in respiratory function was superior with benralizumab, as shown by previous findings.15,16 This drug is the one that obtained the best results in terms of reduction of hospitalizations and exacerbations as well. Furthermore, patients in the benralizumab group were those with the greatest respiratory impairment at baseline (FEV1 60.5%), an aspect that made the improvement in FEV1 even more important than just the numerical increase. Moreover, we obtained a significant steroid-sparing effect with benralizumab (although lower than mepolizumab) and improvements in ACT and ACQ, but not in AQLQ. These data, together with the lower baseline OCS dose (4.4 mg) compared to the mepolizumab-treated subgroup could suggest a greater stability of asthma in benralizumab-treated patients, confirmed by the lowest number of pre-treatment exacerbations (2.4) compared to the other subgroups. Regarding omalizumab treated population, the improvements in FEV1, ACT, ACQ and AQLQ were significant, confirming the effectiveness of this proven and always effective drug. The lower baseline OCS dose (2.4 mg) compared to the one in patients treated with mepolizumab and benralizumab should be highlighted, as it is compatible with the phenotype of patients eligible for omalizumab (“early onset” allergic asthma with fewer comorbidities). It is relevant that subjects enrolled in this subgroup achieved almost complete OCS-weaning, considering that for omalizumab the OCS sparing effect data are less robust than other biologics; no randomized clinical trials (RCTs) based on this important outcome have been conducted, although some open-label and real-life studies indicated the positive effect of omalizumab on the reduction of OCS and consequently the impact on the reduction of the OCS-related complications.17,18 It is necessary to point out that the greater percentage (65%) of atopic patients in the enrolled population compared to those subsequently treated with omalizumab (27%) was due to the fact that a part of these subjects were not eligible for anti-IgE due to elevated IgE values and/or excessive body weight.

Regarding exacerbations rate, all 3 monoclonal antibodies (mAbs) allowed a significant reduction, although the best results were obtained in patients treated with mepolizumab and omalizumab (who also had a higher number of exacerbations at baseline). This latest mAb is the one that has obtained the highest percentage of super responder patients, confirming its reliability despite being the first biologic introduced for the treatment of SRA. However, this finding may have been influenced at least partially by the smaller number of patients in the benralizumab group.

The results on BT were positive and reassuring about the efficacy of this non-drug treatment. We previously mentioned how this non-pharmacological option is often reserved for patients who are not eligible or non-responders to biologics or with T2-“low” asthma. Therefore, BT can be seen as a last resort option, also due to the lack of general consensus on identifying the ideal patient. Compared to biological drugs, no changes in biomarkers, in particular BEC and IgE, were observed. Respiratory function also did not improve, so BT appeared worse than biologics. However, interesting data emerged about significant reduction in hospitalizations and exacerbations that were comparable to the result of mepolizumab and omalizumab, whilst superior to benralizumab. The OCS-sparing effect was also significant, even more important as it was achieved in a subpopulation with a higher baseline prednisone dose (14.6 mg) compared to the sub-population treated with mAbs. ACT, ACQ and AQLQ scores also improved significantly, supporting BT effectiveness on improving asthma control and QoL. In the RISA RCT, OCS use decreased by 63.5% in BT-treated patients, compared with 26.2% and 20% in the control group. Significant improvements in QoL and asthma symptom scores were observed up to 4 months after the steroid weaning phase.19 A real-life study on a small population confirmed the clinical efficacy of BT but even showed an increased need for rescue courses of OCS.20

As for therapeutic switches, these were infrequent and occurred mainly between omalizumab and BT sub-groups. Twenty percent of patients were switched between omalizumab and BT. This was due to non-response to anti-IgE or clinical worsening during the course of treatment and they were ineligible for other biologics. It is important to note that the clinical benefits and the OCS-sparing effect after BT also allowed this subgroup of patients to obtain an improvement in asthma control and to avoid important OCS side effects.

As limitations of this paper, we must recognize that this is a retrospective observational study and not an RCT. A control arm is not available and a selection bias in the choice of treatments may be present. However, there are currently no other published data that compare results of different mAbs with BT and there are no RCT in progress.21 Probably, the major limitation of this study is the difference in the number of patients included in the various treatment groups, which may have led to bias in patient inclusion. However, such differences may be acceptable in a real-life retrospective study.

Concordance in results of the different treatments is the most innovative and interesting aspect of this study and it provides important information on outcomes of different therapeutic options in patients with SRA and different phenotypes treated in a real-world setting.